Cagini Carlo, Pellegrino Adriana, Iannone Alessia, Cerquaglia Alessio, Modugno Antonella, Fiore Tito, Messina Marco
Department of Biomedical and Surgical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, Piazza Menghini 1, 06126 Perugia, Italy.
Department of Surgery and Biomedical Sciences, University of Perugia, Perugia, Italy.
Ther Adv Ophthalmol. 2020 Sep 21;12:2515841420924304. doi: 10.1177/2515841420924304. eCollection 2020 Jan-Dec.
The aim of this study is to compare the efficacy of different dexamethasone eye drops formulations in controlling postoperative inflammation.
Cataract surgery was carried out in 72 patients (35 males) divided into two groups: group A (36 patients, mean age = 78.0 ± 5.6) received four times daily for 2 weeks a suspension containing tobramycin 0.3% mg/ml + dexamethasone 0.1% mg/ml, and group B (36 patients, mean age = 76.2 ± 6.8) a solution containing tobramycin 0.3% mg/ml + dexamethasone 0.1% mg/ml. Both groups received ofloxacin 0.5% four times daily for 7 days, and nepafenac 0.1% three times daily for 3 weeks. Best-corrected visual acuity, intraocular pressure, corneal thickness, endothelial cells count, aqueous flare and macular thickness were evaluated preoperatively and at 1 day, 15 days, 1 and 2 months.
In group A, intraocular pressure, corneal thickness and aqueous humour flare values preoperatively and at the end of follow-up were 14.3 ± 1.8 and 13.2 ± 1.8 mmHg, 546.4 ± 34.6 and 539.6 ± 36.1 µm, 11.84 ± 4.44 and 13.52 ± 5.54 ph/ms, respectively, with no statistically significant difference. In group B, intraocular pressure, corneal thickness and aqueous humour flare values preoperatively and at the end of follow-up were 14.3 ± 1.5 and 13.1 ± 1.7 mmHg, 552.9 ± 37.4 and 548.1 ± 39.3 µm, 11.45 ± 4.06 and 13.73 ± 4.99 ph/ms, respectively, with no statistically significant difference. No difference was detected in the macular thickness values in the parafoveal area preoperatively and at 2 months follow-up in group A (332.18 ± 16.19 and 337.71 ± 16.33 µm) and group B (329.11 ± 18.28 and 334.37 ± 20.86 µm), respectively.
The two different formulations of dexamethasone eye drops reached the same anti-inflammatory effects.
本研究旨在比较不同地塞米松滴眼液制剂在控制术后炎症方面的疗效。
72例患者(35例男性)接受白内障手术,分为两组:A组(36例患者,平均年龄 = 78.0 ± 5.6岁)每天4次,持续2周,使用含0.3%毫克/毫升妥布霉素 + 0.1%毫克/毫升地塞米松的混悬液,B组(36例患者,平均年龄 = 76.2 ± 6.8岁)使用含0.3%毫克/毫升妥布霉素 + 0.1%毫克/毫升地塞米松的溶液。两组均每天4次使用0.5%氧氟沙星,持续7天,每天3次使用0.1%奈帕芬酸,持续3周。术前及术后1天、15天、1个月和2个月评估最佳矫正视力、眼压、角膜厚度、内皮细胞计数、房水闪光和黄斑厚度。
A组术前及随访结束时的眼压、角膜厚度和房水闪光值分别为14.3 ± 1.8和13.2 ± 1.8 mmHg、546.4 ± 34.6和539.6 ± 36.1 µm、11.84 ± 4.44和13.52 ± 5.54 ph/ms,差异无统计学意义。B组术前及随访结束时的眼压、角膜厚度和房水闪光值分别为14.3 ± 1.5和13.1 ± 1.7 mmHg、552.9 ± 37.4和548.1 ± 39.3 µm、11.45 ± 4.06和13.73 ± 4.99 ph/ms,差异无统计学意义。A组(332.18 ± 16.19和337.71 ± 16.33 µm)和B组(329.11 ± 18.28和334.37 ± 20.86 µm)术前及随访2个月时黄斑中心凹旁区域的黄斑厚度值无差异。
两种不同制剂的地塞米松滴眼液抗炎效果相同。